Clinical trials: Breast Cancer, Metastatic Breast Cancer
NSCLC, Breast Cancer
A Study of YL202 in Selected Patients With Advanced Solid Tumors
This study is a multicenter, open-label, phase II study of YL202 in China to evaluate the efficacy, safety, and PK characteristics of YL202 in the following selected patients with advanced solid tumors.
- Conditions
- NSCLC, Breast Cancer, HNSCC, Locally Advanced or Metastatic Solid Tumors
- Trial name
- NCT06107686
- Testing
- YL202 should be intravenously infused
- Where
- 82 sites in China
- Volunteers
- 200 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Breast Cancer
Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)
The goal of this clinical research study is to find the highest tolerable dose of seliciclib that can be given in combination with liposomal doxorubicin to patients with metastatic breast cancer.
- Trial name
- NCT01333423
- Testing
- Liposomal Doxorubicin, Seliciclib
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Breast Cancer
Cipterbin Combined With Vinorelbine in the Treatment of HER2-positive MBC
To compare pharmacokinetics Index of Cipterbin combined with Vinorelbine Injection every week or every three weeks in the treatment of patients with HER2-positive metastatic breast cancer
- Trial name
- NCT05131841
- Testing
- Cipterbin Combined With Vinorelbine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer
Secondary Adjuvant Long Term Study With Arimidex
The study assesses the effect of further 2 years vs further 5 years of adjuvant treatment with anastrozole after initial 5 years of adjuvant endocrine therapy.
- Trial name
- SALSA (NCT00295620)
- Testing
- Anastrozole
- Where
- 60 sites in Austria
- Volunteers
- 3,484 people
- Sponsor
- AstraZeneca
Metastatic Breast Cancer, Chemotherapy-induced Alopecia
Scalp Cooling in MBC
This research is being done to compare rates of hair loss of people with metastatic breast who use scalp cooling versus those who do not use scalp cooling after receiving standard of care treatment with either sacituzumab…
- Trial name
- NCT04986579
- Testing
- Paxman Scalp Cooling System, Eribulin, Sacituzumab govitecan
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer, HER2 Positive Breast Cancer
Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer
The purpose of this study is to see if IPI-504 in combination with trastuzamab is an effective treatment in HER2 positive metastatic breast cancer
- Conditions
- Breast Cancer, HER2 Positive Breast Cancer, Metastatic Breast Cancer, Cancer of the Breast
- Trial name
- NCT00817362
- Testing
- IPI-504, Trastuzumab
- Where
- 11 sites in United States, Spain
- Volunteers
- 29 people
- Sponsor
- Infinity Pharmaceuticals, Inc.
Metastatic Breast Cancer
Letrozole in the Treatment of 1st and 2nd Line Hormone Receptor Positive Breast Cancer: Pre-therapeutic Risk Assessment
The course of the disease in female patients with metastatic mammary carcinoma can vary greatly. In this connection, the individual prognosis depends on a complex interaction of tumor- and patient-related factors.
- Trial name
- NCT00241046
- Testing
- Letrozole
- Volunteers
- 13 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Breast Cancer
Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine
The investigators hypothesize that the administration of Toripalimab (anti-PD-1 antibody, JS001) combined to metronomic Vinorelbine may be an interesting therapeutic option for female patients with HER2- metastatic breast cancer.
- Trial name
- NCT04389073
- Testing
- Vinorelbine 40mg, Toripalimab 240mg, Bevacizumab 5 mg/kg
- Where
- 2 sites in China
- Volunteers
- 138 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Breast Cancer
A Study of The Safety Profile of First-line Avastin (Bevacizumab) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Her2-negative Breast Cancer (AVATAX)
This single arm, open label study will assess the safety profile of Avastin (bevacizumab) in combination with paclitaxel as first-line treatment in patients with locally recurrent or metastatic Her2-negative breast cancer.
- Trial name
- NCT01156961
- Testing
- bevacizumab [Avastin], paclitaxel
- Sponsor
- Hoffmann-La Roche
Metastatic Breast Cancer
Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane Use in Metastatic Breast Cancer
This is a retrospective medical record abstraction study. It is a review and evaluation of up to 300 metastatic breast cancer patients treated with Abraxane or other taxanes such as paclitaxel and docetaxel to determine the…
- Trial name
- NCT00876070
- Where
- 2 sites in United States
- Volunteers
- 198 people
- Sponsor
- SCRI Development Innovations, LLC
Breast Neoplasms, Neoplasm Metastasis
A Research Study of CP-724,714 in Patients With HER2 Overexpressing Metastatic Breast Cancer
The main purpose of this research study is to see if the study drug, named CP-724,714, can help in the treatment of certain breast cancers that have spread to other locations in the body.
- Trial name
- NCT00102895
- Testing
- CP-724,714
- Volunteers
- 25 people
- Sponsor
- Pfizer
Advanced Unresectable or Metastatic Breast Cancer
A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients
The study is being conducted to evaluate the efficacy, and safety of dexmedetomidine hydrochloride nasal spray for preoperative sedation in adults.
- Trial name
- NCT06679036
- Testing
- HRS-2189, Fluvustat, HRS-8080
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Solid Tumor
A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors
In phase Ia study, the safety and tolerability of SI-B003 in patients with recurrent or metastatic solid tumors will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum…
- Trial name
- NCT04606472
- Testing
- SI-B003
- Where
- 8 sites in China
- Volunteers
- 60 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Estrogen Receptor Positive, HER2/Neu Negative
Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer
This randomized phase II trial studies the side effects and how well fulvestrant and palbociclib with or without copanlisib work in treating patients with hormone receptor positive, HER2 negative, stage IV breast cancer.
- Conditions
- Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Stage IV Breast Cancer AJCC v6 and v7
- Trial name
- NCT03377101
- Testing
- Copanlisib, Fulvestrant, Laboratory Biomarker Analysis
- Sponsor
- National Cancer Institute (NCI)
Neoplasms, Breast
Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer
This phase II study will evaluate and compare the efficacy and tolerability of two dose schedules (1500 mg QD and 500 mg BID) of oral Lapatinib as treatment for patients with advanced or metastatic breast cancer.
- Trial name
- NCT00089999
- Testing
- Lapatinib
- Where
- 31 sites in United States, Chile and 9 more
- Volunteers
- 138 people
- Sponsor
- GlaxoSmithKline
Breast Neoplasms
Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer
This study is to evaluate the safety of SU011248 in combination with paclitaxel in patients with metastatic or locally recurrent breast cancer who have not received chemotherapy treatment in the advanced disease setting.
- Trial name
- NCT00174434
- Testing
- SU011248, Paclitaxel
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Pfizer
Breast Cancer
Vaccine Therapy in Treating Women With Metastatic Breast Cancer
RATIONALE: Vaccines made from breast cancer cells may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccines made from breast cancer cells in treating women with…
- Trial name
- NCT00003184
- Testing
- BCG vaccine, CD80 breast cancer vaccine, sargramostim
- Where
- United States
- Sponsor
- Providence Cancer Center, Earle A. Chiles Research Institute
Metastatic Breast Cancer
Optimizing Quality of Life in Women Living With Metastatic Breast Cancer
The purpose of this study is to develop and tailor an intervention program to improve the quality of life in women living with metastatic breast cancer.
- Trial name
- NCT04374825
- Testing
- Acceptance and Commitment Therapy (ACT), Cognitive Behavioral Stress Management (CBSM)
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Northwestern University
Metastatic Breast Cancer ( HER2 Negative)
Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer
This study aims to evaluate whether ^68Ga-TROP2 PET/CT, combined with ^18F-FDG PET/CT, can predict the efficacy of anti-TROP2 antibody-drug conjugates in patients with advanced HER2-negative breast cancer.
- Trial name
- NCT07471776
- Testing
- Sacituzumab Govitecan、Datopotamab deruxtecan、Sacituzumab tirumotecan, 68Ga-TROP2 PET/CT Imaging, 18F-FDG PET Imaging
- Where
- 2 sites in China
- Volunteers
- 45 people
- Sponsor
- Fudan University
HR+ HER2- Breast Cancer
Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
The study is a Phase 1b/2, multi-center, open-label, dose escalation trial evaluating the safety and preliminary efficacy of sapanisertib and serabelisib (PIKTOR) with fulvestrant and/or other anticancer therapies in participants…
- Trial name
- NCT07558733
- Testing
- Serabelisib, Sapanisertib, Fulvestrant
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- Faeth Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.